Top Page
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
(Sydney:RMD)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) vs. iShares MSCI Australia ETF (EWA)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Earnings Call Summary
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.42B | 5.15B | 4.69B | 4.22B | 3.58B | 3.20B |
| Gross Profit | 3.29B | 3.05B | 2.66B | 2.36B | 2.02B | 1.84B |
| EBITDA | 2.08B | 1.92B | 1.53B | 1.36B | 1.18B | 1.10B |
| Net Income | 1.49B | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M |
Balance Sheet | ||||||
| Total Assets | 8.51B | 8.17B | 6.87B | 6.75B | 5.10B | 4.73B |
| Cash, Cash Equivalents and Short-Term Investments | 1.43B | 1.21B | 238.36M | 227.89M | 273.71M | 295.28M |
| Total Debt | 1.00B | 851.81M | 899.21M | 1.58B | 917.55M | 793.72M |
| Total Liabilities | 2.18B | 2.21B | 2.01B | 2.62B | 1.74B | 1.84B |
| Stockholders Equity | 6.33B | 5.97B | 4.86B | 4.13B | 3.36B | 2.89B |
Cash Flow | ||||||
| Free Cash Flow | 1.79B | 1.65B | 1.29B | 559.30M | 195.11M | 619.89M |
| Operating Cash Flow | 1.92B | 1.75B | 1.40B | 693.30M | 351.15M | 736.72M |
| Investing Cash Flow | -270.10M | -200.04M | -269.78M | -1.16B | -229.92M | -158.46M |
| Financing Cash Flow | -802.05M | -606.25M | -1.12B | 422.87M | -128.36M | -764.63M |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Risk Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$53.40B | 21.91 | 26.73% | 0.95% | 11.99% | 32.89% | |
72 Outperform | AU$11.94B | 33.69 | 50.70% | 0.24% | 31.88% | 39.10% | |
70 Outperform | AU$11.37B | 10.64 | 6.32% | 4.69% | 9.44% | -0.37% | |
65 Neutral | AU$12.60B | 26.40 | 20.11% | 1.64% | 4.32% | 9.24% | |
54 Neutral | $9.82B | 12.30 | 0.38% | 2.25% | 6.82% | -99.27% | |
53 Neutral | AU$31.69B | 22.26 | ― | 0.44% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events
ResMed Chairman emeritus and director Peter C. Farrell has reported the sale of 2,000 shares of ResMed common stock at a price of $251.31 per share, leaving him with beneficial ownership of 64,773 shares. The transaction, dated 4 February 2026, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 12 August 2025, indicating the sale was part of a structured diversification or liquidity strategy rather than a discretionary market-timed trade, and offering stakeholders transparency into insider dealings.
The disclosed sale is relatively modest in the context of Farrell’s remaining holdings and does not signal a significant reduction in his equity stake. For investors and corporate governance observers, the filing underscores ongoing insider ownership at the board level while highlighting the use of Rule 10b5-1 plans to manage potential conflicts of interest and perceptions around trading by senior insiders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed’s Global General Counsel and Secretary, Michael J. Rider, reported the sale of 50 shares of ResMed common stock at a price of $260.00 per share, leaving him with beneficial ownership of 9,691 shares. The transaction, dated 4 February 2026, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 28 February 2025, indicating a scheduled personal portfolio adjustment rather than a discretionary sale, with limited direct impact on the company’s operations or strategic positioning.
Such insider transactions are closely watched by investors for signals about executive confidence, though the relatively small size of this sale suggests it is unlikely to materially affect market perception of ResMed’s outlook. The filing underscores ongoing adherence to U.S. securities regulations and structured compliance practices around insider trading, providing transparency for shareholders and regulators regarding executive equity activity.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported an increase in the number of CHESS Depositary Interests (CDIs) quoted on the ASX for January 2026, with total CDIs on issue rising to 580,546,240 from 579,449,490, a net increase of 1,096,750 driven by net transfers between CDIs and common stock listed on the NYSE. Over the same period, the pool of underlying securities over which CDIs have not been issued fell, reflecting transfers between ASX-quoted CDIs and NYSE-listed shares, new share issuance tied to employee equity plans, and share repurchases on the NYSE, underscoring ongoing capital management activity and routine adjustments to the company’s cross-border share structure.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed’s chief financial officer, Brett Sandercock, has reported the sale of 1,000 shares of ResMed common stock at a price of $257.03 per share, leaving him with beneficial ownership of 85,495 shares. The transaction, executed on 2 February 2026, was carried out under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025, signalling that the sale was part of a scheduled diversification or liquidity strategy rather than a discretionary move, and is unlikely to indicate a change in the company’s operational outlook.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$53.20 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed its Form 10-Q for the quarter ended December 31, 2025, confirming that it remains a large accelerated filer in full compliance with U.S. Securities and Exchange Commission reporting requirements and electronic data submission standards. The quarterly report includes unaudited condensed consolidated financial statements, management’s discussion and analysis, risk factor disclosures, and other required information, underscoring the company’s ongoing transparency to investors and regulators and providing an updated view of its financial condition, capital structure, and governance status, including share count and treasury share levels.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed’s chairman and chief executive officer, Michael J. Farrell, reported changes in his beneficial ownership of the company’s common stock following the exercise of stock options and subsequent sale of shares executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2024. Farrell exercised options to acquire 4,991 shares at an exercise price of $146.34 per share and then sold the same number of shares at a weighted average price of approximately $248.46, leaving him with 466,223 shares held directly and additional shares held indirectly through a family trust, a routine insider transaction that modestly adjusts but maintains a substantial equity stake in the company’s leadership alignment with shareholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. disclosed that director and chairman emeritus Peter C. Farrell sold 2,000 shares of ResMed common stock on 7 January 2026 at a price of $248.83 per share under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. Following the transaction, Farrell continues to hold 66,773 shares directly, indicating an ongoing, though slightly reduced, equity stake in the company by a long-standing board member, with no operational changes or strategic shifts signaled in the filing.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed has scheduled the release of its financial and operational results for the second quarter of fiscal 2026 for January 29, 2026, after the close of trading on the New York Stock Exchange, followed by a management webcast to discuss the performance. The webcast, accessible exclusively via the company’s investor relations website, will provide investors and other stakeholders with detailed insight into quarterly results, with on-demand replay options available online and via phone, underscoring Resmed’s ongoing investor communication efforts and transparency around its financial and operational trajectory.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has disclosed that Chief Executive Officer and Director Michael J. Farrell intends to sell 4,991 shares of the company’s common stock on or about January 7, 2026, through Fidelity Brokerage Services LLC, under a Rule 144 filing. The shares, valued at roughly $1.24 million based on the filing’s aggregate market value, were acquired via stock options granted in November 2019 and exercised for cash, and follow Farrell’s prior open-market sales of a total of 16,020 shares in October and November 2025, signaling continued executive share disposals that may draw investor attention to insider selling activity and capital management at the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed director Peter C. Farrell has filed a notice of proposed sale of company securities under SEC Rule 144, disclosing his intention to sell 2,000 common shares of ResMed through broker Merrill Lynch on the New York Stock Exchange. The filing shows that the shares to be sold were acquired via stock options exercised for cash in November 2024, and also details that Farrell sold a total of 4,000 ResMed shares in two prior transactions over the past three months, indicating ongoing, structured share disposals by an insider under a pre-adopted trading plan dated August 12, 2025, which may be viewed by investors as routine insider portfolio management rather than a signal of undisclosed negative information about the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Global General Counsel and Secretary, Michael J. Rider, has reported the sale of 50 shares of ResMed common stock on 2 January 2026 at a price of $241.75 per share, leaving him with beneficial ownership of 9,741 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 28 February 2025, indicating the sale was made according to a preset schedule and may help mitigate concerns about discretionary insider trading among investors and other stakeholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s chief financial officer, Brett Sandercock, has reported the sale of 1,000 shares of ResMed common stock on 2 January 2026 at a price of $241.75 per share, in a transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. Following the sale, Sandercock continues to hold 86,495 ResMed shares directly, indicating that the trade represents a small portion of his overall stake and appears to be part of a structured diversification or liquidity program rather than a change in senior management’s overall alignment with shareholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc., whose NYSE-listed common stock is traded on the ASX via a 10:1 CHESS Depositary Interest structure under the code RMD, reported updated figures for its CDI and underlying securities on issue for December 2025. The total number of CDIs on issue over quoted securities increased slightly to 579,449,490, a net rise of 62,160 over the month, mainly due to net transfers between CDIs and common stock listed on the NYSE. The company also reported movements in its non-CDI securities, with a net decrease reflecting transfers between ASX CDIs and NYSE common stock, issuance of new shares related to employee stock options, restricted stock units and purchase plans, and ongoing share repurchases on the NYSE, indicating active capital management and routine adjustments to its cross-listed share structure.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has disclosed that company officer Brett Sandercock plans to sell 1,000 common shares on or around 2 January 2026 through Fidelity Brokerage Services LLC, with an aggregate market value of about $241,750, under a previously adopted Rule 10b5-1 trading plan dated 19 February 2025. The filing also notes that Sandercock, who acquired these shares as restricted stock vesting in November 2022 as part of his compensation, sold a total of 4,000 ResMed shares in the prior three months for gross proceeds of nearly $987,000, providing investors with additional visibility into planned insider share disposals and trading activity but representing a small fraction of the company’s roughly 146 million shares outstanding.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
An executive of ResMed Inc., officer Michael J. Rider, has filed a notice of proposed sale of company common stock under Rule 144, covering 50 shares to be sold on the NYSE through Fidelity Brokerage Services. The shares, valued at roughly $12,088 in aggregate, were acquired as restricted stock that vested in November 2023 as part of compensation, and follow a previous sale of 50 shares in December 2025, signaling a small, routine liquidity move rather than a material change in insider holdings or company operations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chairman and CEO, Michael J. Farrell, reported changes in beneficial ownership of the company’s common stock. The transactions, conducted under a pre-established Rule 10b5-1 plan, involved the acquisition and subsequent sale of shares, reflecting strategic financial management by the company’s leadership. These transactions may influence investor perceptions and highlight the company’s ongoing commitment to aligning executive interests with shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported a change in beneficial ownership, with Peter C. Farrell, a director and significant shareholder, disposing of 2,000 shares of common stock at a price of $251.47 per share. This transaction, conducted under a pre-established Rule 10b5-1 plan, reflects ongoing adjustments in the company’s shareholder structure, potentially impacting investor perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has filed a notice of proposed sale of securities under Rule 144, indicating the sale of 2,000 common shares with an aggregate market value of $502,860. The shares are to be sold by Peter C Farrell, a director of the company, and are scheduled for sale on December 3, 2025, on the NYSE. This transaction may impact the company’s stock liquidity and shareholding structure, potentially influencing investor perception and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced an update regarding its CHESS Depositary Interests (CDIs), with a net increase of 918,810 CDIs over quoted securities for November 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options, restricted stock units, and employee stock purchase plans. The company also reported a decrease in other securities, reflecting strategic adjustments in its stock management, including share repurchases on the NYSE. These movements indicate ResMed’s ongoing efforts to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has announced a proposed sale of 1,000 common shares by Brett Sandercock, an officer of the company, under Rule 144 of the Securities Act of 1933. This transaction, set to occur on December 1, 2025, follows previous sales of 3,000 shares each in September, October, and November 2025, reflecting a strategic move by the officer to liquidate a portion of his holdings. The sale is valued at approximately $244,160 and will be conducted through Fidelity Brokerage Services LLC on the NYSE, indicating a continued trend of share sales by company insiders, which could have implications for investor perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has filed a Form 144 with the SEC, indicating a proposed sale of 50 shares of common stock by Officer Michael J. Rider. The shares, acquired through restricted stock vesting, are set to be sold on December 1, 2025, on the NYSE with an aggregate market value of $12,208. This filing is part of a planned transaction under Rule 10b5-1, ensuring compliance with insider trading regulations. The sale is not expected to impact the company’s operations or market position significantly, as it represents a small fraction of the total shares outstanding.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.